1st Qtrly 17-18 2nd Qtrly 17-18 3rd Qtrly 17-18 4th Qtrly 17-18 31st ANNUAL REPORT 2016-2017
1st Qtrly 16-17 2nd Qtrly 16-17 3rd Qtrly 16-17 4th Qtrly 16-17 30TH ANNUAL REPORT 2015-2016
1st Qtrly 15-16 2nd Qtrly 15-16 3rd Qtrly 15-16 4th Qtrly 15-16 29TH ANNUAL REPORT 2014-2015
1st Qtrly 14-15 2nd Qtrly 14-15 3rd Qtrly 14-15 4th Qtrly 14-15 28TH ANNUAL REPORT 2013-2014
1st Qtrly 13-14 2nd Qtrly 13-14 3rd Qtrly 13-14 4th Qtrly 13-14 27TH ANNUAL REPORT 2012-2013
1st Qtrly 12-13 2nd Qtrly 12-13 3rd Qtrly 12-13 4th Qtrly 12-13 26TH ANNUAL REPORT 2011-2012
1st Qtrly 11-12 2nd Qtrly 11-12 3rd Qtrly 11-12 4th Qtrly 11-12 25TH ANNUAL REPORT 2010-2011

COLINZ LABORATORIES LIMITED
A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER 2012

  (Rupees in '000')
S. No. Particulars Un -audited Un-audited Audited
Quarter Ended Half Year Ended Year
30.09.2012 30.06.2012 30.09.2011 30.09.2012 30.09.2011 31.03.2012
PART-l (a)Income from Operation            
1 Gross Sales 19,157 23,253 17,762 42,410 39,734 70,455
  less Excise Duty 1,264 1,547 1,130 2,811 1927 4,435
  Net Sales/Income From Operation
17,893
21,706
16,632
39,599
37,807
66,020
  (b) Other Operating Income - - - - - -
  Total Income from Operation 17,893 21,706 16,632 39,599 37,807 66,020
2 Expenses            
  (a) Cost Of Material Consumed 7,088 5,984 6,833 13,072 13,070 24,418
  (b) Purchase of Stock in Trade 1,504 1,870 1,349 3,374 2,037 3,457
  (c) Change in Inventories Of Finished Goods and Work in Progress of Stock in trade (2,224) 2,389 (1,974) 165 2,453 (1,095)
  (d) Employee Benefit Expenses 6,592 6,881 6,178 13,473 11,619 22,545
  (e) Depreciation & Amortisation Expenses 653 653 644 1,306 1,289 2,599
  (f) Other Expenses 3,509 3,112 3,052 6,621 6,089 11,694
  Total Expenses 17,122 20,889 16,082 38,011 36,557 63,618
3 Profit/(Loss) from Operation Before Other Income ( 1-2) 771 817 550 1,588 1,250 2,402
4 Other Income 248 206 126 454 154 369
5 Profit /(Loss) from ordinary activities before 1,019 1,023 676 2,042 1,404 2,771
  finance cost & Exception items ( 3+4)            
6 Finance Cost 542 537 388 1,079 797 1,893
7 Profit /(Loss) from ordinary activities after finance Cost but before Exceptional items ( 5-6) 477 486 288 963 607 878
8 Exceptional items - -   - - -
9 Profit /(Loss) from ordinary activities before Tax ( 7-8) 477 486 288 963 607 878
10 Tax Expenses ( Provision for Taxation ) Current tax Deffered tax 0 0 0 0 0 158
    0 0 0 0 0 (384)
11 Net Profit/(Loss) From Ordinary Activities after Tax (9-10) 477 486 288 963 607 1,104
12 Paid up Equity Share Capital ( Face Value 10/- Per Share ) [Net of allotment money in arrears] 354,35 354,35 354,35 354,35 354,35 354,35
13

Reserves Excluding Revaluation Reserves

- - - - - 7,630
14

Earning per share (EPS) before extraordinary item( not Annualised)

- - - - - -
  i) Basic & Diluted - - - - 0 0.24
  ii) Diluted - - - - - -
PART-ll

PARTICULARS OF SHAREHOLDING

           
1 Public shareholding            
  i Number of Shares 2,904,901 2,904,900 3,080,150 2,904,901 3,080,150 2,902,900
  ii Percentage of shareholding 63.55% 63.55% 67.38% 63.55% 67.38% 63.51%
2 Promoters and promoter group Shareholding            
  a) Pledged/Encumbered            
  i Number of shares            
  ii Percentage of shares (as a % of the total shareholding of promoter and promoter group)            
  iii Percentage of shares (as a% of the total share capital of the company)            
  b) Non-encumbered            
  - Number of Shares 1,666,099 1,666,100 1,490,850 1,666,099 1,490,850 1,668,100
  - Percentage of shares (as a% of the total shareholding of promoter and promoter group) 36.45% 36.45% 32.62% 36.45% 32.62% 36.49%
  Percentage of shares (as a % of the total share capital of the company) 100% 100% 100% 100% 100% 100%
B INVESTORS COMPLAINTS       3 MONTHS ENDED 30-9-2012
  Pending at Begining of the Quarter         NIL  
  Received During the Quarter         NIL  
  Disposed of During the Quarter         NIL  
  Remaining at the end of the Quarter         NIL  

 

(Rupees in ‘ 000)

STATEMENT OF ASSETS AND LIABILITES
   

PARTICULARS

30.09.2012
(Un-Audited)

31.03.2012
(Audited)

A   CAPITAL & LIABILITIES    
1   Shareholders Funds    
  a) Share Capital 35,435 35,435
  b) Reserve and Surplus 27,313 26,345
    Total 62,748 61,780
2   NON CURRENT LIABILITIES    
  a) Long term borrowing 26,126 23,918
  b) Deffered tax liability( net) 3,100 3,100
  c) Other long term liability 116 98
  d) Long term Provision - -
    Total 29,342 27,116
3   CURRENT LIABILITIES    
  a) Short term borrowing - -
  b) Trade payable 8,027 9,126
  c) Other current liabilities 5,893 4,147
  d) Short term provision - -
    Total 13,920 13,273
         
    Total (1+2+3) 106,010 102,169
B   ASSETS    
1   NON CURRENT ASSETS    
  a) Fixed Assets 41,073 42,361
  b) Non current investments 3,159 3,159
  c) Long terms loan and advance 13,544 13,763
  d) Other Non current assets 6,530 4,289
    Total 64,306 63,572
    CURRENT ASSETS    
2 a) Inventries 21,337 21,333
  b) Trade receivable 16,150 10,843
  c) Cash and cash equivalents 3,307 5,494
  d) Short term loan and advances 910 927
    Total 41,704 38,597
         
    Total (1+2) 106,010 102,169

 

NOTES :-

  1. The above financial results have been taken on record at a meeting of Board of Directors held on 31-10-2012
  2. The Company operates in single segment of manufacture of pharmaceutical formulations. Hence Accounting Standard on segment reporting is not applicable.
  3. Previous period figures have been regrouped wherever required.

 

  For and on behalf of the Board
  M/s. COLINZ LABORATORIES LIMITED
   
Mumbai Dr. L. S. Mani
31.10.2012 Chairman & Managing Director.

 

(Top)

Contact:
A/101, Pratik Estate,
Mulund Link Road,
Next to Fortis Hospital,
Mumbai-400078.
Tel.: 91-22-25668002/3
Fax: 91-22-25668006.
Email: cllfindoc@yahoo.com
Website:www.findoc-cll.in
Email:info@findoc-cll.in